Academic journal
POPULARITY
In this episode, we sit down with Sarah Hormachea, MS, RD, CDCES, BC-ADM, a Diabetes Care and Education Specialist whose work spans national guideline committees, tribal community health, and clinical practice. Sarah breaks down how medical nutrition therapy (MNT) for type 1 diabetes has transformed—moving away from rigid, prescriptive diet rules and toward individualized, culturally inclusive care.She shares what's changed in the latest nutrition guidelines, how technology and real-time glucose insights are reshaping patient conversations, and what the first year after diagnosis really looks like for many people. Sarah also dives into emerging research, from plant-forward approaches to ketogenic patterns, gut health, and medication advances that could influence nutrition strategies in the years ahead.Listeners will also learn where to find reliable resources, how to stay connected with the latest developments, and how to access Sarah's work and insights.Sarah Hormachea is a Diabetes Care and Education Specialist who believes nutrition therapy should honor both culture and science. Drawing on 10+ years in clinical and community settings, she helps make diabetes care more personal, inclusive, and effective.“Sometimes it takes these diagnoses for people to stop and reflect and recognize that health is wealth, right? And if you have, if you don't have your health - what do you have?”Question of the Day:How has nutrition played a role in how you (or a loved one) manages or navigates type 1 diabetes? On This Episode You Will Learn:How Diabetes Care and Education Specialists (DCES) support people with type 1 diabetes at every stage of care.The most important updates from recent medical nutrition therapy guidelines—and why they matter.What early nutrition support looks like immediately after diagnosis and during the first year.Common nutrition myths in type 1 diabetes and how to approach them with evidence and compassion.The research and trends poised to shape the future of type 1 diabetes nutrition care.Connect with Yumlish!Yumlish Website: YumlishYumlish on Instagram: @yumlish_Yumlish on Facebook: YumlishYumlish on Twitter: @yumlish_Yumlish on LinkedIn: YumlishConnect with Sarah Hormachea!Website URL: www.sarahhormachea.com Instagram URL: https://www.instagram.com/sarah.hormachea/ Facebook URL: https://www.facebook.com/sarahhormachea.diabetescare LinkedIn URL: https://www.linkedin.com/in/sarahhormachea/
Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?Cuidados com doença aguda (sick day) e hipovolemiaCuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho, Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss major diabetes technology updates alongside key technology-related changes in the 2026 American Diabetes Association Standards of Care. The conversation highlights how rapidly evolving devices and updated guidelines are converging to reduce treatment burden and expand access to advanced diabetes management tools. The discussion opens with updates from Dexcom, notably the launch of the Dexcom G7 15-day sensor, which incorporates an updated algorithm and is already integrating with Omnipod 5 and iLet systems, with Tandem integration expected soon. The hosts also address the announcement that the Dexcom G6 will be retired in July 2026, acknowledging the emotional and practical challenges this poses for patients who prefer the G6's connectivity and perceived accuracy. While the transition may be difficult for some, the longer wear time and algorithm improvements of the G7 are framed as an opportunity to reassess CGM options and prepare thoughtfully for change. Attention then shifts to Omnipod 5, with anticipation around a forthcoming software update planned for 2026. This update will introduce a lower glucose target of 100 mg/dL, down from 110 mg/dL, and significantly reduce automated-mode “kick-outs.” The hosts emphasize that minimizing time out of automated insulin delivery is critical for improving time in range and lowering patient burden, noting that excessive safety-driven exits can paradoxically worsen glycemic control. A substantial portion of the episode is devoted to technology-focused updates in the 2026 ADA Standards of Care, reflecting Bellini's perspective as a guideline committee member. Key changes include the removal of C-peptide and autoantibody requirements as barriers to insulin pump and automated insulin delivery (AID) access, reinforcing that insulin use, not diabetes type, should guide eligibility. The guidelines now include a Level A recommendation for AID use in type 2 diabetes, supported by recent clinical trial data and regulatory approvals. Additional updates expand support for CGM use during pregnancy beyond type 1 diabetes, reduce reliance on confirmatory fingerstick language, and strengthen recommendations for connected insulin pens for individuals on multiple daily injections when AID is not preferred or feasible. The episode concludes with discussion of expanded guidance on open-source AID systems, underscoring the importance of clinician understanding and patient support regardless of FDA approval status. Collectively, Isaacs and Bellini frame the 2026 updates as a decisive step toward earlier, broader, and more individualized use of diabetes technology across care settings. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: American Diabetes Association. The American Diabetes Association Releases “Standards of Care in Diabetes—2026” | American Diabetes Association. Diabetes.org. Published December 8, 2025. Accessed December 17, 2025. https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2026 American Diabetes Association Professional Practice Committee for Diabetes*. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12. doi:10.2337/dc26-SREV Chapters 00:00:00 - Intro & Agenda: New Tech + 2026 ADA Standards 00:00:45 - Dexcom G7 15‑Day Sensor & G6 Retirement 00:04:40 - OmniPod Algorithm Update 00:09:27 - 2026 ADA Standards of Care 00:15:45 - Expanding Diabetes Tech Options 00:21:19 - Endorsement of Earlier AID and Open-Source AID Support
Coming to you from the #NCPA2025 expo floor, host John Beckner and co-host Ed Cohen talk with Brian Connelly, president and CEO of TheracosBio, about Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with Type 2 diabetes. They discuss how the company's model bypasses PBMs to offer pharmacists and patients a fair, transparent price.
In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening, Diagnosis and Treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Alina M. Allen, M.D. Associate Professor of Medicine at Mayo Clinic in Rochester, Minnesota, where she serves as the Director of Hepatology and Director of the MASLD Clinic. Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082
Dr. Sunil Gupta addressed several common diabetes-related myths—especially those that spread during festivals—such as the false belief that diabetes spreads through touch, that bitter gourd juice is a cure, or that eating sweets directly causes diabetes. He clarified that such misconceptions can misguide people and delay proper care. Dr. Gupta explained that tingling or numbness in the hands and feet is not always due to high sugar levels; it can also be caused by nerve pressure, sitting posture, or Vitamin B12 deficiency. In Type 2 diabetes, medicines may reduce with disciplined lifestyle changes, but complete cure is rare. Diabetes may get “reversed” in specific situations such as gestational diabetes after delivery, stress-induced diabetes, or after bariatric surgery. He also highlighted that children's late-night gaming habits harm mental health and sometimes require psychological guidance. Dr. Gupta discussed the stages of Diabetic Retinopathy, noting that retinal damage cannot be reversed, though progression can be slowed with timely treatment. Conditions like Vitamin D3/B12 deficiency, infections, high BP, or glaucoma can also affect vision—so both diabetes and eye specialists should be consulted. Dr. Gupta emphasized that diabetes is a lifestyle condition and individuals should not be labeled as “patients.” Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 11/10/2019 Recorded at: Akashwani Nagpur
Scott and Jenny discuss bolusing for Sonic Tater Tots Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Throughout the session, Dr. Sunil Gupta shared practical and easy-to-follow advice on managing diabetes effectively in daily life. He emphasized the importance of moderation during festivals, advising people to enjoy the “sweetness of words” rather than consuming excessive sweets. A positive attitude, self-discipline, and mindful choices, he said, are crucial for maintaining good health. Dr. Gupta encouraged individuals with diabetes to monitor their blood sugar regularly using a glucometer or continuous glucose monitoring (CGM) system to understand their glucose trends and make timely adjustments in diet, medication, and physical activity. Highlighting that 50–70% of people with diabetes are overweight, he explained the “Fit Fat Concept,” which means that even if a person carries extra weight, staying active and physically fit can significantly reduce diabetes-related risks. He also recommended avoiding HFSS foods (High Fat, High Salt, and High Sugar) and instead including more fiber-rich foods, vegetables, and fruits in the daily diet. Stressing the importance of consistent exercise, proper hydration, and stress control, Dr. Gupta concluded that diabetes management goes beyond medicines — it requires awareness, lifestyle balance, and a positive mindset for long-term well-being. Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 25/10/2019 Recorded at: Akashwani Nagpur Episode: 96
Dr. Sunil Gupta shared key insights for diabetes patients. Diabetes affects not just the pancreas but blood vessels throughout the body, with the liver being particularly vulnerable. Hyperinsulinemia (excess insulin) and long-term high blood sugar, high cholesterol, and high triglycerides can lead to fatty liver, which may progress to fibrosis or cirrhosis of liver. Dr. Gupta emphasized that human insulin is safe and effective, while insulin analogs (ultra-fast and ultra-long) are more physiologically aligned with the body's needs. Doses should be adjusted based on weight. Every person with diabetes should have a glucometer, as frequent monitoring helps control sugar levels and adjust doses. Diet and lifestyle play a crucial role. Limit sugar, jaggery, sweets, and honey, and prefer brown rice for its lower glycemic index. Exercise, weight management, and controlling blood pressure and cholesterol are essential. Foot care, eye check-ups, and avoiding alcohol, smoking, and tobacco are vital. For children with Type 1 diabetes, parent training, workshops, and insulin learning programs ensure safe management and prevent complications. Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 14/06/2019 Recorded at: Akashwani Nagpur Episode: 94
We're looking at some major policy issues happening in Washington, and what you can really do to effect change. George Huntley is the CEO of DPAC, the Diabetes Patient Advocacy Coalition. We've got a lot to cover: Medicare changes like competitive bidding that could dramatically limit access to CGMs and insulin pumps for seniors, the changing landscape around GLP 1 meds, and we talk about patient advocacy wins. I know some of you are cynical, but it can work. If you've ever thought your voice doesn't matter, this conversation may change your mind. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections. Keywords Diabetes, D-PAC, Medicare, GLP-1 medications, patient advocacy, healthcare access, insulin pumps, CGMs, diabetes technology, legislative reform AI info below: Summary In this conversation, George Huntley, CEO of the Diabetes Patient Advocacy Coalition (D-PAC), discusses the critical role of advocacy in improving diabetes care and access to technology. He highlights the challenges faced by patients, particularly regarding Medicare coverage for insulin pumps and continuous glucose monitors (CGMs), and the implications of recent legislative changes. The discussion also covers the potential of GLP-1 medications in diabetes management and the importance of patient stories in advocacy efforts. Takeaways D-PAC focuses on affordable and equitable access to diabetes care. Advocacy is crucial for influencing healthcare policies. Competitive bidding for diabetes technology could limit access for seniors. Patient stories are essential in legislative advocacy. GLP-1 medications show promise in reshaping diabetes treatment. Economic factors play a significant role in healthcare access. The aging population of type 1 diabetes patients requires urgent attention. Collaboration among advocacy groups is vital for success. Healthcare costs are driven more by major medical expenses than by drug prices. Continued advocacy is necessary to protect patient access to care. Chapters 00:00 Introduction to Diabetes Advocacy 03:01 The Role of D-PAC in Diabetes Care 05:53 Challenges in Medicare Coverage for Diabetes Technology 09:11 The Impact of Competitive Bidding on Seniors 11:55 Advocacy Efforts and Legislative Challenges 14:57 The Future of GLP-1 Medications 17:56 Economic Implications of Diabetes Management 21:01 The Importance of Patient Advocacy 23:59 Healthcare Costs and Insurance Dynamics 26:56 The Need for Continued Advocacy 29:54 Conclusion and Call to Action
Listen to our radio program first aired on SBS South Asian on Tuesday, 2 December 2025 at 2 PM, focusing on weekly Australian news, Australian PM's marriage, diabetes care tips, the 16-day anti–gender-violence campaign, native title and land rights and other topics. SBS Nepali is a part of SBS South Asian, the destination channel for all South Asians living in Australia. To hear more audio content from SBS Nepali, subscribe to our podcast on any platform, including Apple Podcasts, YouTube Podcasts, and Spotify. SBS Nepali broadcasts a radio program every Tuesday and Thursday at 2 PM on SBS South Asian digital radio and channel 305 on your TV, live from our studios in Sydney and Melbourne. Repeats of these shows are aired every Thursday and Sunday at 4 PM on SBS Radio 2. Every Monday, listen to one full hour of contemporary Nepali songs on SBS South Asian at 2 PM. - हाम्रो पछिल्लो रेडियो कार्यक्रम सुन्नुभयो? मङ्गलवार, २ डिसेम्बर सन् २०२५ दिउँसो २ बजे एसबीएस साउथ एसियनमा प्रत्यक्ष प्रसारण भएको एसबीएस नेपालीको कार्यक्रममा हामीले पछिल्लो एक हप्ताका अस्ट्रेलियन समाचार, प्रधानमन्त्री एन्थोनी अल्बानिजीको विवाह, मधुमेह रोगको लक्षण र उपचार, नेटिभ टाइटलको वास्तविक अर्थ, नेपाल समाचार लगायत विभिन्न विषयहरू जोडेका छौँ। हाम्रो रेडियो कार्यक्रम हरेक मङ्गलवार र बिहीवार दिउँसो दुई बजे SBS South Asian मा प्रत्यक्ष प्रसारण हुन्छ। यी रेडियो कार्यक्रम बिहीवार र आइतवार SBS Radio 2 मा अपराह्न ४ देखि ५ बजेसम्म पुन प्रसारण हुन्छन्। डिजिटल रेडियोमा SBS South Asian, डिजिटल टिभीको च्यानल 305 मा अथवा SBS Audio App डाउनलोड गरेर पनि श्रोताहरूले यी कार्यक्रम सुन्न सक्नुहुन्छ। यसै गरी SBS on Demand मा गएर वा हाम्रो वेबसाइट sbs.com.au/nepali मार्फत पनि हाम्रो प्रत्यक्ष प्रसारण सुन्न सकिन्छ।
Dr. Michael Snyder joins Dr. Forbes to discuss research showing that Type 2 diabetes represents multiple metabolic subtypes rather than a single condition. He explains how glucose curve patterns, oral glucose tolerance testing, and continuous monitoring can help identify differences in muscle insulin resistance, beta-cell function, hepatic signaling, and incretin response. The conversation explores how these physiological patterns may guide individualized nutrition strategies, medication selection, and earlier detection in people with emerging dysregulation.
In this episode of Sg2 Perspectives, host Jayme Zage, PhD is joined by Sg2 experts Emily Fitt and Rhae Ana Gamber to discuss evolving diabetes care trends through both clinical and strategic lens. They explore key differences in managing pediatric vs adult populations and type 1 vs type 2 diabetes, along with emerging innovations such as GLP-1 medications, continuous glucose monitors and automated insulin delivery systems. The conversation also highlights the importance of personalized care, social determinants of health, and systemwide planning to meet rising demand and improve outcomes. Sg2 Perspectives Listener Feedback Survey: We would love to hear from you - Please click here We are always excited to get ideas and feedback from our listeners. You can reach us at sg2perspectives@sg2.com, or visit the Sg2 company page on LinkedIn.
Brooke Green, NP, is a nurse practitioner at Hamilton Diabetes and Endocrinology Center. For more information about Hamilton Diabetes and Endocrinology Center call 706-278-1622 or visit www.VitruvianHealth.com/diabetes. This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.
This issue will review: 1. Screening Natriuretic Peptide Levels Predict Heart Failure and Mortality in Individuals with Type 1 and Type 2 Diabetes without Known Heart Failure 2. The Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications In Patients with Type 2 Diabetes 3. Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes – JAMA Network Open 4. An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program A Randomized Clinical Trial 5. Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study 6. Change in urine albumin-to-creatinine ratio and clinical outcomes in patients with chronic kidney disease and type 2 diabetes Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, breakdown recent trial news from the 2 most popular incretin therapies: semaglutide and tirzepatide. First, hosts breakdown the November 24, 2025 announcement from Novo Nordisk disclosing their evoke and evoke+ trials of oral semaglutide in early symptomatic Alzheimer Disease failed to slow disease progression. Next, hosts break down the TIRTLE study, which examined use of tirzepatide in patients with type 1 diabetes. Semaglutide Misses Mark in Alzheimer Disease Novo Nordisk announced top-line results from the evoke and evoke+ phase 3 trials showing oral semaglutide 14 mg did not slow disease progression over 2 years in adults with early symptomatic Alzheimerdisease, with no significant difference in CDR-SB change versus placebo. Despite improvements in Alzheimer-related biomarkers across both studies, neither trial demonstrated a slowing of clinical decline. evoke was a global, randomized, double-blind, placebo-controlled trial enrolling 1,855 participants aged 55–85 with amyloid-positive CDR 0.5 MCI or CDR 1.0 mild dementia, treated 1:1 with semaglutide or placebo for 104 weeks plus a planned 52-week extension. evoke+ mirrored this design, randomizing 1,953 participants with the same eligibility criteria to daily semaglutide 14 mg or placebo for a total planned duration of 156 weeks. Findings from the trials will be presented at the 2025 Clinical Trials in Alzheimer's Disease (CTAD) conference on December 3, 2025. The lack of efficacy led to discontinuation of the planned 1-year extension period across both trials, though safety and tolerability remained consistent with prior semaglutide experience in diabetes and obesity. TIRTLE: Tirzepatide Shows Benefit in Type 1 Diabetes In a 12-week, double-blind, placebo-controlled phase 2 trial of 24 adults with type 1 diabetes and BMI >30 kg/m², tirzepatide produced a 10.3-kg mean weight loss versus 0.7 kg on placebo, an −8.7-kg treatment difference (P < 0.0001) corresponding to 8.8% total body weight reduction. All tirzepatide-treated participants achieved ≥5% weight loss, and 45% achieved ≥10%, compared with 9% and 0% in the placebo group. Eligibility criteria required patients to be 18 years of age or older, with confirmed type 1 diabetes, obesity (BMI >30), and stable insulin therapy. Tirzepatide also improved glycemic control, reducing HbA1c by 0.4%, and decreased total daily insulin dose by 35% relative to placebo (−24.2 vs −0.3 units/day). Safety data suggested no significant adverse events occurred, with 22 of the 24 participants completing the study. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Novo Nordisk. Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. Novo Nordisk. November 24, 2025. Accessed November 24, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462. Snaith JR, Frampton R, Samocha-Bonet D, Greenfield JR. Tirzepatide in Adults With Type 1 Diabetes: A Phase 2 Randomized Placebo-Controlled Clinical Trial. Diabetes Care. Published online November 20, 2025. doi:10.2337/dc25-2379
On this accredited episode of NP Pulse: The Voice of the Nurse Practitioner®️, expert faculty Drs. Korey Hood and Kathryn Evans-Kreider explore the psychosocial challenges of living with type 1 diabetes, with a focus on how nurse practitioners can support patients experiencing diabetes distress. Faculty discuss practical strategies, such as using brief screening tools, adopting person-first and strengths-based language and tailoring care through shared decision-making. The conversation also highlights the impact of SDOH and the importance of integrating mental health awareness into routine diabetes management. This podcast is part of the Clinical Advantage Bootcamp: Type 1 Diabetes Management Certificate for Nurse Practitioners. Visit the AANP CE Center to view the other modules. A participation code will be provided at the end of the podcast — make sure to write this code down. Once you have listened to the podcast and have the participation code, return to this activity in the AANP CE Center. Click on the "Next Steps" button of the activity and: 1. Enter the participation code that was provided. 2. Complete the posttest. 3. Complete the activity evaluation. This will award your continuing education (CE) credit and certificate of completion. 1.0 CE will be available through Nov. 30, 2027. Tool link : Diabetes_Billing_and_Coding_Toolkit.pdf This collaboration between AANP and Danatech, an Association of Diabetes Care and Education Specialists (ADCES) initiative, is made possible thanks to grants from Helmsley Charitable Trust, Abbott and Medtronic.
Dr. Sunil Gupta explained that diabetes is common in adults over 65 years and often occurs alongside other health issues such as high blood pressure, cholesterol, heart, kidney, or eye problems. Managing diabetes in seniors typically follows a stepwise approach: diet and exercise first, followed by oral medications, and insulin if needed. Blood sugar fluctuations can be dangerous in elderly people, so regular monitoring is essential. If a meal is missed or appetite is low, blood sugar should be checked, and light food, fruits, or milk can be consumed by them. Dr. Gupta emphasized that special care is required for those with comorbid conditions, and newer medications help control blood sugar without increasing the risk of hypoglycemia. Similarly, modern insulin formulations can lower the risk of nocturnal hypoglycemia by up to 30–40%. Foot care in elderly is critical, as poor circulation and nerve damage increase the risk of infections or amputations. Regular foot checks, proper footwear, and avoiding smoking or tobacco are essential. He also noted that Type 1 diabetes, common in children aged 5–15, can occur at any age. Parents should attend training to manage insulin and handle emergencies at home. Regular check-ups and doctor consultations are crucial to prevent complications and maintain overall health in both seniors and children. Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 28/06/2019 Recorded at: Akashwani Nagpur Episode: 93
Dr. Sunil Gupta highlighted several key aspects of diabetes management, emphasizing the importance of balance, awareness, and regular monitoring. He explained that both glucose and fructose are simple carbohydrates, but glucose has a glycemic index of 100, while fructose is slightly lower. Eating sweets or sugary foods leads to a rapid spike in blood sugar, so it is better to avoid fruit juices and consume whole fruits instead, as their fiber helps reduce the glycemic load and glycemic index. People with controlled diabetes should choose low-sugar fruits such as apple, jamun (black plum), and papaya, while high-sugar fruits like mango, chikoo, pineapple should be taken in limited quantities—around 50 grams or two slices. Including protein and complex carbohydrates in meals helps slow sugar absorption and prevents nighttime low sugar (hypoglycemia). Dr. Gupta further explained that swelling in the body can be due to kidney problems, heart failure, liver disease (such as Non-Alcoholic Fatty Liver Disease), or certain diabetes medications; in such cases, both salt and water intake should be limited. He stressed that about 70% of diabetic patients die from heart attacks or brain strokes, making regular heart check-ups is essential even if the ECG appears normal. Because diabetes weakens immunity, infections occur more easily, and wounds heal slowly; hence, maintaining blood sugar control is vital. To prevent hypoglycemia, one should eat something every three to four hours. Finally, he advised that diabetes screening should be done at least once a year—or earlier if symptoms like fatigue, weight loss, or frequent urination appear. Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 24/05/2019 Recorded at: Akashwani Nagpur Episode: 92
Diabetes care is not just restricted to a person but it is a social challenge, and therefore both families and society must be educated about it. Dr. Sunil Gupta explained the normal blood sugar range, the effects of hypoglycemia and hyperglycemia, and how diabetes impacts digestion and metabolism. He discussed diabetes in women, obesity, and the “fit-fat” concept, explaining that even people with normal weight can have internal fat called “visceral fat” that increases diabetes and heart attack risk. Dr. Gupta highlighted that lack of sleep, stress, and an undisciplined lifestyle are major contributors to the rise in diabetes. He described discipline, a balanced diet, regular exercise, and an informed society as the key elements to achieving a “Diabetes Complication-Free India.” Dr. Gupta also mentioned that unexplained weight loss in diabetes could indicate thyroid disorders or other underlying conditions. He concluded with a simple yet powerful message: “Eat less, walk more, sleep well, stay stress-free, and help build an educated, healthy society.” Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 25/01/2019 Recorded at: Akashwani Nagpur Episode: 91
Researchers from Virginia Tech have discovered that ultra-processed meats and beverages are the worst for brain health. Individuals who consumed one or more extra servings of either of these foods showed a significantly increased risk of developing cognitive impairments, including those associated with forms of dementia such as Alzheimer's Disease. A recent article from Children's Health Defense shared new research ranking which junk foods are most harmful to the brain — and it's not just about kids' waistlines or sugar highs. It's about how what we eat can shape how we think, learn, and even feel. Let's dig into what this new research is saying, and more importantly, what it means for our families. How Junk Food Impacts the Brain These studies found that foods loaded with refined sugar, unhealthy fats, and artificial ingredients don't just harm the body — they change how the brain functions. Think of it like this: the brain runs on clear signals, kind of like a radio station. When it's getting clean fuel — whole foods, real nutrients — that signal is clear. But when it's constantly fed ultra-processed foods, it's like turning up the static. The brain starts to lose focus, memory gets fuzzy, and mood and motivation can shift. Ultra-Processed Foods (UPFs) are now known to include obesity, type 2 diabetes, cardiovascular diseases, anxiety, depression, and an increase in all-cause mortality. In fact, according to a study published in Diabetes Care, a journal of the American Diabetes Association, up to 220,000 young Americans under age 20 are likely to have Type 2 diabetes by 2060 — a 673% increase from 2017 levels. One of the studies found that people who ate a lot of processed meats, fried snacks, and sugary drinks had measurable changes in the areas of the brain that control memory and emotion. Another study showed that even short-term diets high in sugar and fat can rewire how the brain's “reward center” works — making people crave those same foods even more. A study of nearly 124,000 people found that drinking just one daily serving of artificially sweetened drinks increased the risk of a liver disease known as nonalcoholic fatty liver disease or metabolic dysfunction. That means the more we eat these foods, the more our brains want them, creating a loop that's hard to break. Why Kids Are Especially Affected Recent research has shed light on a startling concern—more than 300 chemicals have been detected in babies' cord blood and placenta at birth. This discovery highlights the fact that exposure to harmful chemicals begins much earlier than we previously thought. From conception through pregnancy, toxins can pass from the mother to the fetus, raising concerns about their potential long-term effects on child development and health. Children's brains are still developing, which makes them much more sensitive to these kinds of foods. When a growing brain is constantly exposed to sugary, processed foods, it can interfere with how nerve connections form. Some of the research cited by Children's Health Defense found that kids and teens who eat a lot of junk food have more trouble with memory and learning, and can experience more mood swings or attention issues. Part of that is because junk foods crowd out the nutrients that developing brains need — like omega-3s, zinc, and iron. And part of it is chemical: those processed ingredients can actually change the way the brain's reward systems respond, which makes healthy foods less appealing over time... Click Here or Click the link below for more details! https://naturallyrecoveringautism.com/233
Hear about the promise of combination therapies and dual and triple agonists in helping people with obesity lose weight and improve overall health. Credit available for this activity expires: 11/11/26Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003041?ecd=bdc_podcast_libsyn_mscpedu
StartUp Health community member Katharine Barnard-Kelly, PhD, CEO & Co-founder of Spotlight-AQ, joins StartUp Health co-founder Unity Stoakes to share how her team is transforming diabetes care by giving providers a window into their patients' real lives. In this inspiring conversation, Dr. Barnard-Kelly explains how Spotlight-AQ's AI-driven clinical tool helps providers deliver holistic, biopsychosocial care that improves outcomes for patients, reduces burnout for clinicians, and saves costs for health systems. In this episode: How Spotlight-AQ uses AI to match each patient's real-world experience with optimal routine care The simple, three-minute questionnaire that helps providers focus on what matters most Why holistic care is critical for managing chronic conditions like diabetes and obesity Lessons from Dr. Barnard-Kelly's journey from health psychology to health tech entrepreneurship How Spotlight-AQ achieved FDA qualification for a person-reported outcome measure in diabetes What's next after earning second place in the 2025 Breakthrough T1D Israel Innovation Challenge Why being part of the StartUp Health community has been so valuable for connection and collaboration Tune in to hear how Dr. Katharine Barnard-Kelly is building a bridge between science and clinical practice – and making biopsychosocial care the new standard for precision medicine. Are you ready to tell YOUR story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of our Health Moonshot PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.
In this special episode on a Beta Cell Update Dr. Neil Skolnik discusses this emerging area with Dr. Melena Bellin. This special episode is supported by an independent educational grant from Sanofi. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Melena Bellin. Professor, Pediatric Endocrinology, and Surgery, Co-Director, Total Pancreatectomy and Islet Autotransplant Program and the Albert D. and Eva J. Corniea Chair, University of Minnesota/ Masonic Children's Hospital Selected References: Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care 2024;47(8):1276–1298 An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019;381:603-613 Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement . Diabetes 2020;69(10):2037–2047 Resources for Auto-antibody Testing: Type 1 Diabetes TrialNet Centers of Excellence Locations Type 1 Risk test Trialnet
In this episode of The Huddle, Janice Baker, MBA, RDN, CDCES, CNSC, BC-ADM, joins Julia Socke, RDN, LDN, CDCES, for an insightful conversation on common nutrition myths and the importance of holistic diabetes care. Drawing on nearly 43 years of experience, Janice shares her evidence-based perspectives on topics like low-carb diets, artificial sweeteners, and protein. She also discusses her collaborative approach to working with other healthcare providers and highlights often-overlooked aspects of diabetes management—such as foot and dental care—that contribute to truly comprehensive patient support. Join us for an enlightening discussion that blends clinical expertise with practical strategies for whole-person diabetes care. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This issue will review: 1. Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis - Diabetes Care 2. Orforglipron, an Oral Small-Molecule GLP-1Receptor Agonist, in Early Type 2 Diabetes – NEJM 3. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment – NEJM 4. Dementia Risk in People With Type 1 Diabetes and Associated Risk Factors – Diabetes Care 5. Impact of baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and CKD – Diabetes Care 6. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity - NEJM Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
Until recently, Jeremy Auger's diabetes was unstable. Then he met endocrinologist Dr. David Campbell and the team with the diabetes mobile clinic in Calgary. The roving clinic brings care directly to people who are homeless or have low incomes. For patients like Jeremy, it's a lifeline that helps prevent devastating complications.
Dr. Sunil Gupta explained that during the summer season, people with diabetes are at higher risk of dehydration, low blood sugar, and infections, making it essential to stay well-hydrated with fluids like water and buttermilk. Discussing diet, Dr. Gupta recommended moderation in mango and fruit intake, emphasizing that fruit juices should be avoided because they can cause rapid spikes in blood sugar. He also addressed the importance of caution during fasting periods, such as Ramadan or religious fasts, when there is a risk of hypoglycemia (low sugar). In such cases, he stressed that medication adjustments must be made under medical supervision. For those traveling or unwell, Dr. Gupta suggested following travel and sick-day guidelines—carrying two sets of medicines, a glucometer, and glucose tablets, and never discontinuing medications during illness or vomiting. He warned that dehydration can worsen diabetes control. Concluding his advice, Dr. Gupta reminded that diabetes cannot be completely cured, but with proper lifestyle management, it can be effectively controlled for a healthy, active life. Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 19/04/2019 Recorded at: Akashwani Nagpur Episode: 90
Kent Schnakenberg returns to share how one bike ride turned into a life's mission—raising awareness, saving lives, and inspiring thousands through Team Snack Strong and the fight against type 1 diabetes. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Dr. Sunil Gupta explained that the prevalence of diabetes in pregnancy (gestational and pre-gestational) is high and may vary from 5% to 20% in different populations in India. He said that 90% of women may not have any symptoms of diabetes, but others may experience symptoms such as frequent vaginal infections, polyuria (increased urination), polyphagia (increased hunger), polydipsia (increased thirst), unexplained weight loss, and fatigue, etc. Dr. Gupta said that frequent nighttime urination may be one of the symptoms of diabetes. He clarified the difference between Type 1 and Type 2 diabetes, especially the causes and presentation in children. Addressing common myths, he emphasized that regular use of prescribed medication does not cause serious side effects. Answering a question on increased urinary frequency, he explained that recurrent urinary tract infections (UTIs) and autonomic bladder neuropathy are often overlooked complications causing such symptoms. He highlighted that maintaining proper blood sugar control before and during pregnancy is essential to prevent complications for both the mother and the baby. Dr. Gupta also stressed the importance of timely testing, diet management, exercise, and insulin dose adjustment during pregnancy. Concluding his session, he advised that the entire family should take collective responsibility for supporting the expectant mother, calling it a shared “pregnancy project” to ensure a safe and healthy outcome for both mother and child. Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 22/03/2019 Recorded at: Akashwani Nagpur Episode: 89
Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.In this episode, I sit down once again with returning guest and college athlete Jaci Carpenter for an honest conversation about the realities of navigating diabetes care as a young adult. From frustrating endocrinology visits and inflated medical costs to learning how to advocate for yourself and manage nutrition beyond “just taking insulin for what you eat,” this episode shines a light on what so many people with diabetes face every day.Our Deep Dive Includes:Why Jaci's recent endocrinology experience left her classified as a “high-risk diabetic” — and what that really meansHow the healthcare and insurance systems often fail those who are doing everything rightThe emotional and financial weight of affording insulin, CGMs, and pump suppliesLearning to question outdated medical advice and advocate for your own careThe difference between textbook diabetes management and real-life diabetes management as an athleteWhy nutrition is more than carb counting — and how to make food choices that support long-term health and stabilityFinding balance between discipline, mental health, and living your life freely with diabetes
In this education program through Vividh Bharati (All India Radio), Dr. Sunil Gupta explained in detail that diabetes is a multifactorial disease that can affect multiple organs including the eyes, nerves, liver, kidneys, heart, and even sexual health. He highlighted that non-alcoholic fatty liver disease (NAFLD), sleep disturbances, frozen shoulder, and sexual dysfunction are among the common complications associated with diabetes. He elaborated that diabetes medications—such as Metformin, Glitazones, and SGLT2 inhibitors—work in different ways: some drugs like sulfonylureas increase insulin secretion, others improve insulin sensitivity, while some help eliminate excess sugar through urine. Dr. Gupta clarified that starting medication does not necessarily mean lifelong dependency; if blood sugar levels remain under good control, the dosage can be reduced under dose monitoring or, in some cases, the medication can be stopped under medical supervision. Concluding his address, he emphasized that “the true treatment of diabetes is not just controlling blood sugar but taking care of the whole body through a disciplined and healthy lifestyle.” Expert- Dr Sunil Gupta Anchor- Mrs. Shraddha Bharadwaj Podcast: 22/02/2019 Recorded at: Akashwani Nagpur Episode: 87
In this episode of the RCP Medicine Podcast, Dr Vincent Simpson, diabetes and endocrine registrar based in Derriford, Plymouth joins Dr Bryony Alderman, palliative medicine consultant and RCP Education Fellow in Sustainability. Together, they explore the intersection of diabetes care and environmental sustainability, focusing on Vincent's pioneering work around reusable cartridge insulin pens.From the initial spark of curiosity during a training session to national-level conversations with NHS England, Vincent shares his journey of uncovering the environmental impact of diabetes devices and advocating for change. The discussion covers practical steps clinicians can take, the importance of behavioural change, and how small interventions can lead to significant improvements in both patient care and environmental outcomes.Whether you're a physician, policymaker, or someone living with diabetes, this episode offers valuable insights into how sustainability can be seamlessly integrated into clinical practice.Dr Vincent Simpson and team recently won an RCP Excellence in Patient Care award for Sustainability – reducing the environmental impact of healthcare ResourcesPaper: https://onlinelibrary.wiley.com/doi/10.1111/dme.15409Local guidelines: https://sustainablediabetes.short.gy/guidelinesWebsite: https://sustainablediabetescare.comLinkedin: https://uk.linkedin.com/in/dr-vincent-simpsonBluesky:https://bsky.app/profile/drvsimpson.bsky.socialCreditsDr Bryony Alderman, consultant in palliative medicine, is the RCP Sustainability Fellow. Financial support for this clinical fellowship was provided as an Independent Medical Education Grant from Pfizer Limited. Pfizer Limited had no involvement in candidate selection, and no influence on the work of the clinical fellowship.RCP Links Education Events Membership Improving care Policy and campaigns RCP Social Media Instagram LinkedIn Facebook X Bluesky Music: Episode 50 onward - Bensound.com Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas
Scott talks with Marley, mom to one-year-old Bane, diagnosed after DKA and a life flight. From ICU to CGM and Mobi, she shares hard-won reality, faith, and growing TikTok advocacy. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Join Dr. Cecilia Lansang, Associate Editor of Endocrine Practice, Professor of Medicine, and Director of Endocrinology at Cleveland Clinic, as she speaks with Dr. Kristen Flint, Interim Director of Quality and Safety for Endocrinology at Massachusetts General Hospital, Attending Endocrinologist at MGH, and Instructor at Harvard Medical School, about her team's quality improvement project, “Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care.” This episode covers:Strategies for implementing quality improvement interventions in a large academic diabetes specialty clinicKey interventions that increased CGM utilization, including targeted provider education, workflow optimization, and patient outreachLessons for advancing equitable implementation and sustaining quality improvement over time Tune in for practical insights on bridging policy changes and clinical practice to improve CGM access for Medicare patients. Read the full article in the August 2025 issue of Endocrine Practice here.
Dr. Sunil Gupta explained that Type 2 Diabetes is a multifactorial disorder, influenced by several interconnected factors such as genetics, obesity, physical inactivity, unhealthy diet, and stress. He highlighted that even people who appear lean or fit can develop diabetes due to visceral fat—the hidden fat that accumulates around internal organs and disrupts metabolism. Dr. Gupta elaborated that unexplained weight loss in diabetes often occurs when insulin deficiency causes glucose to be excreted through urine. However, he cautioned that persistent or sudden weight loss may sometimes signal other underlying conditions such as tuberculosis or cancer and should not be ignored. He also discussed sarcopenia—the loss of muscle mass commonly seen in people with diabetes—and emphasized the importance of sufficient protein intake, muscle-building resistance exercise, regular physical activity, and a well-balanced diet in preserving muscle strength and metabolic health. Proper exercise, he noted, improves insulin sensitivity and overall blood sugar control. Concluding his address, Dr. Gupta warned that individuals whose blood sugar levels remain above 180 mg/dL (HbA1c > 7%) for long periods are at higher risk of weight loss and other severe complications. He urged everyone to adopt a proactive lifestyle with mindful eating, exercise, and regular medical check-ups for long-term diabetes management. Expert- Dr Sunil Gupta Anchor- Mrs.Kalyani Gokhale Podcast: 3/10/2025 Recorded at: Akashwani Nagpur Episode: 86
In the All India Radio (Vividh Bharati) program, Dr. Sunil Gupta emphasized that effective diabetes management extends beyond medication and relies equally on mental peace, emotional balance, and a positive outlook—what he calls “glycemic happiness.” Stress, anxiety, and depression, he explained, can disrupt blood sugar control and heighten the risk of complications, making emotional well-being a key component of diabetes care. He urged individuals to focus on early detection of prediabetes and to adopt timely lifestyle modifications to delay or even prevent the progression of the disease. Balanced nutrition, regular physical activity, and consistent monitoring, he said, form the foundation of long-term diabetes control. Dr. Gupta also highlighted the worrying trend of diabetes affecting younger age groups, often due to sedentary routines, poor dietary habits, and increasing stress levels. He advised maintaining a positive mindset, staying active, and adhering to regular medical check-ups and prescribed therapy. Awareness and education, he stressed, are vital to empowering individuals to take control of their health. Concluding his message, Dr. Gupta warned that diabetes is a “sweet killer”—a silent condition that can cause serious harm if ignored but can be effectively prevented and managed through awareness, timely intervention, and adopting a disciplined, healthy lifestyle. Expert- Dr Sunil Gupta Anchor- Mrs. Manjusha Ambulkar Podcast: 1/10/2025 Recorded at: Akashwani Nagpur Episode: 85
Dr. Sunil Gupta began his address by extending warm greetings for Navratri and emphasized the importance of maintaining moderation and dietary discipline during festivals. He explained that “low blood sugar” (hypoglycemia) can be more dangerous in elderly individuals and that diabetes management goals should be personalized according to a person's age and associated health conditions. He elaborated on the concepts of “Thrifty Genotype” and “Thrifty Phenotype,” explaining that both our genetic makeup and poor nutrition during pregnancy contribute to the rising burden of diabetes. Addressing the younger generation, he advised adopting a healthy lifestyle, regular physical activity, and effective stress management to reduce the genetic risk. He stated “Genes are the loaded guns, It's the environment which pulls the trigger.” Responding to audience questions, Dr. Gupta provided simple and practical insights on topics such as hypoglycemia, liver and kidney health, and managing low blood sugar. He concluded by stating that awareness, regular check-ups, and a balanced lifestyle are the most effective keys to keeping diabetes under control. Expert- Dr Sunil Gupta Anchor- Mrs.Kalyani Gokhale Podcast: 26/09/2025 Recorded at: Akashwani Nagpur Episode: 84
In this special series on Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated steatohepatitis (MASH) our host, Dr. Neil Skolnik will discuss Epidemiology, Importance, Screening and treatment of MASH. This special episode is supported by an independent educational grant from Boehringer Ingelheim. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Jay Shubrook, D.O., Professor and Diabetologist in the Department of Clinical Sciences and Community Health At Touro University California College of Osteopathic Medicine Selected references: Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care 2025;48(7):1057–1082
This issue will review: 1. Once-weekly Ultra-processed Foods and Diet Quality in Association With Long-term Weight Change and Progression to Type 2 Diabetes Among Individuals With a History of Gestational Diabetes Mellitus—A Prospective Study 2. Plant-Based Dietary Patterns Associated With Reduced Risk of All-Cause Mortality in Diabetes Subgroups 3. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes- NEJM 4. Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study 5. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
Katharyne, 47, was diagnosed with type 1 diabetes at the start of 2025 and is still in her honeymoon phase. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
In part 1 and 2 we explored the document “Person-Centered Conversations: Weight Management and Type 2 Diabetes” that was put out by the Association of Diabetes Care and Education Specialists (ADCES) as a “framework” document. Reader Emily wrote in to ask if I would analyze it as she has recently been told to use it in her work as a diabetes educator. In Part 1 we looked at the basics, in part 2 the conversation recommendations. Today we're going to look at what they are calling “Continuing the conversation” Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe
What if I told you that diabetes doesn't have to be a life sentence? In this episode of the Visibly Fit Podcast, I sit down with Timothy Keller, who went from facing a devastating diabetes diagnosis to completely reversing it—without relying on a stack of prescriptions.Tim shares his raw and real journey, from unhealthy habits and a shocking lab report to discovering the healing power of God's design through whole foods and lifestyle medicine. Not only did he restore his own health, but he also founded U.S. Diabetes Care to help thousands of others break free from the cycle of “sick care” and step into true health.This conversation is so much more than just about diabetes. It's about hope, faith, and realizing that your health choices impact generations to come. Whether you're facing a diagnosis, struggling to make lasting changes, or simply want to prevent disease and feel your best, this episode will give you both the inspiration and the tools to take charge of your health.Chapters:[00:00] Podcast Preview[01:34] Topic and Guest Introduction[05:10] Tim's Personal Health Journey[08:32] The Birth of U.S. Diabetes Care[12:45] Revolutionizing Diabetes Education[16:08] Understanding Diabetes Types[20:02] The Emotional Aspect of Health[23:30] Encouraging Change in Others[26:04] Telehealth and Accessibility[30:05] Continuous Glucose Monitoring Technology[33:50] Tim's Bold Final Encouragement[37:38] Final Thoughts and ResourcesResources mentioned:
Jenny and Scott talk about bolusing for CTC. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Jasmine Gonzalvo, PharmD, MPH, CDCES, FADCES, and Honey Yang Estrada, MPH, CHW, join this episode to discuss the vital role of community health workers (CHWs) in diabetes care. They share strategies for recruiting CHWs, integrating them into interprofessional care teams, and leveraging their lived experience to build trust and address barriers beyond the clinic walls. The conversation emphasizes listening to CHWs, fostering sustainable partnerships, and shifting power to communities—not just checking a box—to reduce disparities and drive better outcomes. Listen to more episodes of The Huddle at adces.org/perspectives/the-huddle-podcast.Learn more about ADCES and the many benefits of membership at adces.org/join.
Physician Daryna Bahriy discusses her article "How Ukrainian doctors kept diabetes care alive during the war," sharing how medical teams in western Ukraine adapted to protect vulnerable patients amid the chaos of conflict. Daryna explains how disrupted supply chains threatened insulin access, how doctors rapidly coordinated resource redistribution, and how patient education initiatives provided life-saving guidance in bomb shelters. She reflects on the importance of leadership, foresight, and humanity in medicine during crisis. Listeners will learn how health systems can prepare for instability, support chronic disease patients under extraordinary conditions, and draw strength from resilience and solidarity. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended
Laura, 55, was diagnosed with type 1 in March 2024 after months of missed signs, DKA, septic shock, and necrotizing fasciitis. Now on a GLP, she's honeymooning without insulin. Part 1 of 2 Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Megan, 36, has lived with T1D since age 4 and now faces lupus too. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Elle spent years hiding her diabetes, surviving burnout, and even a coma. Now she's leaning in, healing old wounds, and building community through honesty and connection. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Juice Cruise 2026 - Come Sail Away Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
Clara,' a 45-year-old nurse with LADA, shares her fight for a proper diagnosis after bad info from Kaiser—and how growing up with a T1D sister shaped her journey. Go tubeless with Omnipod 5 or Omnipod DASH * Dexcom G7 CONTOUR NextGen smart meter and CONTOUR DIABETES app Get your supplies from US MED or call 888-721-1514 Tandem Mobi twiist AID System Free Juicebox Community (non Facebook) Eversense CGM Medtronic Diabetes Drink AG1.com/Juicebox Touched By Type 1 Take the T1DExchange survey Use code JUICEBOX to save 40% at Cozy Earth Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof. Brown et al. Diabetes Care (2021). Sherr et al. Diabetes Care (2022). Pasquel FJ, et al. JAMA Network Open (2025). Single-arm studies comparing 3 months of Omnipod 5 use to standard therapy in 240 people aged 6-70 years and 80 people aged 2-5.9 years with type 1 diabetes and 305 people aged 18-75 years with type 2 diabetes. Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!